V ascular endothelial growth factor (VEGF) has been implicated as the major angiogenic stimulus responsible for the formation of choroidal neovascularization (CNV) in age-related macular degeneration (ARMD). 1 Drugs that inhibit the bioactivity of VEGF represent a new paradigm in the treatment of neovascular ARMD. Pegaptanib (Macugen; Eyetech Pharmaceuticals, Inc., New York, NY), an anti-VEGF aptamer, was found to be superior to sham injection in phase III trials and was the first anti-VEGF drug to be approved for the treatment of neovascular ARMD. 2 However, its advantage was manifested mainly by slowing the pro-gression of vision loss rather than by improvement of visual acuity. 2 Bevacizumab (Avastin; Genentech Inc., San Francisco, CA) is a Food and Drug Administration-approved anti-angiogenesis drug that is given intravenously in combination with 5-fluorouracil (5-FU) for treating advanced colorectal cancer. 3 It is a humanized monoclonal antibody that binds all isoforms of VEGF (VEGF 110, VEGF 121 , VEGF 145 , VEGF 165 , VEGF 183 , VEGF 189 , and VEGF 206 ). Recently, it has been demonstrated that systemic administration of bevacizumab is effective in patients with neovascular ARMD, improving visual acuity and reducing retinal thickness. 4 However, systemic administration of bevacizumab has been associated with an increased risk of thromboembolic events in cancer patients. 5 Ranibizumab (Lucentis, Genentech Inc.) is a smaller 48-kD Fab fragment derived from the same murine antibody as bevacizumab. 6 In a large prospective study, Ranibizumab showed promising results, including improvement in visual acuity to 20/40 in approximately 40% of treated ARMD patients; furthermore, visual acuity improved by 3 lines in 30% of patients, with a mean increase of 7 letters (Miller JW, ASRS meeting, July 2005, Montreal).
Ranibizumab was developed, in part, because preclinical primate data reportedly showed lack of penetration of intravitreally injected full length IgG beyond the internal limiting membrane (ILM). 7 However, in clinical practice, intravitreal bevacizumab has been found to have a significant biologic effect on retinal edema, subretinal fluid, and pigment epithelial detachments secondary to ARMD 8 (Rosenfeld PJ, Avery RL, Subspecialty Retina Meeting, AAO, October 2005; Chicago) as well as reducing the macular edema of vein occlusions. 9 Because of this disparity, we decided to evaluate the retinal penetration of bevacizumab following intravitreal injection in rabbits.
A further aim of the present study was to evaluate possible toxicity of intravitreally injected bevacizumab in a rabbit model. To test possible bevacizumab toxicity to the ganglion cells as well as to distal retinal layers, we recorded respectively the visual evoked potentials (VEPs) and the electroretinogram (ERG).
Methods

Animals
Ten adult albino rabbits weighing 2.5-3.0 kg each were included in the study. The rabbits were housed under 12/12 hour light-dark cycle and were allowed free access to water and food. All the experimental procedures adhered to the ARVO Resolution on the Treatment of Animals in Research and to institutional guidelines. Before intravitreal injection and electrophysiologic recordings, the rabbits were anesthetized by an intramuscular injection (0.5 mL/kg body weight) of a mixture containing ketamine hydrochloride (10 mg/mL), acepromazine maleate solution (10%), and xylazine solution (2%) at a ratio of 1:0.2: 0.3. Topical anesthesia (benoxinate HCL 0.4%) was administered to reduce the animals' discomfort. The pupils were fully dilated with cyclopentolate hydrochloride 1%. The rabbits underwent clinical inspection by indirect ophthalmoscopy, ERG, and VEP recordings. The ERG responses were recorded from each rabbit before intravitreal injection, 3 hours postinjection to detect immediate functional damage to the retina, and then 3 days and 1, 2, and 4 weeks postinjection to determine possible permanent damage to the retina. Four weeks after injection, the visual evoked potentials were recorded as well. Then, the rabbits were killed by intravenous injection of an overdose of sodium pentobarbital (80 mg/kg body weight).
Bevacizumab (Avastin)
The right eye of each rabbit was injected intravitreally with 0.1 mL bevacizumab solution having a concentration of 25 mg/mL (original vial concentration).
Intravitreal Injection
Each rabbit was injected intravitreally in both eyes as described before. 10 A 28-gauge needle attached to a 1.0-mL tuberculin syringe was inserted into the vitreous approximately 1 mm posterior to the limbus. The syringe was directed under visual control using an indirect ophthalmoscope (Neitz Instruments, Tokyo, Japan) towards the center of the vitreous above the optic disk. A volume of 0.1 mL was then slowly injected. The right eye was always injected with bevacizumab, and is referred to as the experimental eye. The left eye of each rabbit was injected intravitreally with 0.1 mL PBS and served as control.
Following the intravitreal injection the rabbit underwent an ophthalmoscopic examination for detection of retinal injury or cataract formation.
Electroretinogram
Flash ERG responses were recorded 10 from the experimental and control eyes, using corneal electrodes (Medical Workshop, Groningen, The Netherlands). The reference and ground electrodes were made of stainless steel surgical needles, and were inserted into the ears. The ERG signals were amplified (x20,000) and filtered (0. ERG analysis was based on measurements of the b-wave amplitude from the trough of the a-wave to the peak of the b-wave. The b-waves of the experimental and control eyes were plotted as a function of log flash intensity for each eye of each rabbit. The responseintensity curve of the ERG b-wave was fitted to a Michaelis-Menten type hyperbolic function 11 :
where V is the amplitude of the ERG b-wave elicited by a stimulus of intensity I, Vmax is the maximal response amplitude and is the semi-saturation constant. Functional damage in the experimental eye was assessed from the Vmax ratio (experimental/control), and the difference in log (experimental-control).
Visual Evoked Potentials
Flash VEP was recorded using a stainless steel needle as the active electrode that was inserted under the skin above the area of the visual cortex, midway between the two ears. The reference and ground electrodes were inserted in the ears. The signal was amplified (x200,000) and filtered (1-100 Hz) by a differential amplifier (Grass, West Warwick, RI). With this electrode configuration, monocular light stimuli yielded very similar VEPs in nontreated animals. Fifty stimuli were delivered at a rate of 1.1 Hz, and the resultant signals were digitized and averaged by the computer.
The VEP responses were assessed quantitatively from their temporal pattern and amplitudes. The most easily identifiable waves of the flash VEP in rabbits were an initial negative wave that was followed by a prominent positive wave. The VEP amplitude was measured from the trough of the first negative wave to the peak of the following positive wave. Temporal properties of the VEP were defined by the time interval from stimulus onset to the trough of the first negative wave, termed the implicit time.
Immunohistochemistry
Following fixation for at least 24 hours, 4 mm square pieces of retina attached to the retinal pigment epithelium (RPE) were excised from the eye and rinsed in phosphate buffered saline (PBS, pH ϭ 7.2). The tissue was then embedded in low-melt agarose (5%; Sigma, St. Louis, MO) and sectioned at 100 m with a Vibratome (Technical Products International, Polysciences, Warrington, PA). Sections were incubated in normal donkey serum (1:20) overnight in PBS, 0.5% BSA, 0.1% Triton X-100, and 0.1% azide (PBTA). The next day the donkey antihuman antibody conjugated to the fluorochrome Cy3 (1:500 in PBTA; Jackson ImmunoResearch Labs, West Grove, PA) was added overnight. This antibody binds to the heavy and light chains of the humanized bevacizumab IgG antibody. All antibody incubations were done at 4°C on a rotator. The sections were then rinsed in PBTA, mounted on glass slides using 5% n-propyl gallate in glycerol, and viewed on an Olympus Flouview laser scanning confocal microscope.
Results
Clinical Observation
After intravitreal injection, as well as during the follow-up period, no inflammation was observed in any eye. In all eyes injected, the cornea was clear, there was no inflammatory response, the lens and vitreous appeared clear and the fundus intact in both the bevacizumab and the saline injected eyes. Figure 1 shows representative ERG responses of one rabbit that were recorded at five time intervals (3 hours, 3 days, and 1, 2, and 4 weeks) after intravitreal injection of 0.1 mL of the original 25 mg/mL vial solution, namely, an injected bevacizumab dose of 2.5 mg. Dark-adapted ERG responses that were elicited by flashes of different intensities (denoted in log units to the left of each row) are shown for each recording session. The ERG response of the experimental eye (upper trace) is compared to the ERG response of the control eye (lower trace) in each pair of responses. The ERG responses of the rabbit in Figure 1 did not change appreciably during the 4-week follow-up period.
Electroretinogram
The pattern of the bevacizumab effect and its dependency upon time after injection are better illustrated in Figure 2 , showing the response-intensity relationships for the dark adapted b-waves measured at 3 hours (A), 1 week (B), and 4 weeks (C) after bevacizumab injection. The response-intensity data were fitted to the Michaelis-Menten hyperbolic function (equation 1) to derive the maximal b-wave amplitude (Vmax) and semi-saturation constant (), summarized in Table 1 . To asses the effects of bevacizumab on the functional integrity of the experimental eye, we calculated the Vmax ratio (experimental/control eye) and the semisaturation constant (log difference) of b-waves in the dark-adapted state, as shown in Figure 3 , A and B, respectively. For the light-adapted state we calculated the amplitude ratio for the ERG responses evoked by the brightest light flash. Figure 3A summarizes the average Vmax ratio of the rabbits at each postinjection time point. Figure 3B summarizes the average difference in log of the rabbits at each postinjection time point. There was no significant difference in the Vmax of b wave in dark adapted state and the log at all the different time intervals. Figure 4 shows the average amplitude ratio of b waves in the light adapted state at all the different time intervals. Here also there was no significant difference at the different time points.
Visual Evoked Potential
Since bevacizumab penetrated the retina from the vitreal side, the first cells to be exposed to it were the ganglion cells. We recorded the VEPs to test possible bevacizumab toxicity to the ganglion cells and/or to the nerve fiber layer. Figure 5 shows VEP responses elicited by binocular stimulation (upper trace) and by monocular stimulation of the experimental and control eyes (middle and lower rows, respectively) of one rabbit that were recorded 4 weeks after intravitreal injection of bevacizumab. The typical pattern of a negative wave appearing 40 to 60 msec after the light stimulus, followed by a positive wave, was seen in all recordings for experimental and control eyes.
We measured the implicit time of the first negative wave and the amplitude of the positive wave of the VEP responses of all the rabbits, at the 4-week time point, and calculated the amplitude ratio (experimental/control) and the implicit time difference (experimental -control). The average amplitude ratio was 1.06 Ϯ 0.27, and the average implicit time difference was 1.23 Ϯ 5.45. These values did not differ significantly from a ratio of 1.0 and from a difference of 0 for the amplitude ratio and implicit time difference, respectively.
Fig. 3. Electroretinogram (ERG) follow-up for 10 albino rabbits. (A)
Vmax ratio (experimental eye/control eye) was calculated for each rabbit at each ERG recording session. The Vmax ratios of rabbits were averaged for each testing session, to assess bevacizumab toxicity. (B) The effects of bevacizumab on the semi-saturation constant were calculated from the difference between log of the experimental eye and log of the control eye. 
Immunohistochemistry
In the eyes that had been injected with bevacizumab 24 hours before being killed, labeling was observed throughout the retina but not within the RPE or choroid ( Figure 6, A and B) . Specifically, labeling was present in the ILM, the ganglion cell, and inner nuclear layer, as well as in the inner and outer segment layers of the photoreceptors. In some cases, entire Muller cells were labeled. While much of the retinal bevacizumab labeling was extracellular, in some cases it appears that this antibody had been internalized by a subset of cells within the retina. A similar pattern of labeling was observed in eyes that had been injected with bevacizumab 7 days before being killed, although the intensity of Muller cell labeling appeared to increase and essentially no labeling was observed in the inner and outer segment layers ( Figure 6, C and D) . There was no labeling seen in saline injected eyes when the same microscope settings were used as those for the contralateral bevacizumab injected eyes (data not shown). In eyes that had been injected with bevacizumab 4 weeks before being killed, no labeling was observed when the sections were viewed using identical microscope gain settings as those used for the 24 hours and 7 day injected eyes. When the gain was increased significantly, faint labeling of the ILM was detectable ( Figure 6E ) above background autofluorescence which was seen in the uninjected control eyes that were incubated with the donkey antihuman Cy3 (Figure 6F ).
Discussion
The finding of full thickness retinal penetration of this humanized IgG after intravitreal injection contradicts the findings of Mordenti et al., but may help explain the biologic effect of intravitreal bevacizumab seen clinically. 7 There are several possible explanations for the different results obtained in our study and those obtained by the previous primate study. First, different species were used that may react differently to injected antibody. Other differences may also be important. For example, the previous study compared penetration differences between IgG and Fab fragments, and different epitopes were used. 7 The IgG used in the study was one made against human epidermal growth factor 2 (HER2), and the Fab fragment was made against VEGF. The retinal penetration may be different due to the binding of HER2 sites in the inner retina even though the administration of excess unlabeled anti-HER2 antibody in these experiments may have minimized this binding. Another reason may relate a difference in dosage. The previous study used a dose of 25 g, while 2.5 mg was used in our study (which is closer to the 1.25 mg which is being used clinically in humans). 7 This 100-fold increase in dose may overwhelm barriers to diffusion, allowing a small amount of this potent agent to diffuse into the retina and exert a biologic effect. In fact, Han has used very high doses of IgG in rabbits to explore a therapeutic use for treating endophthalmitis. He found full thickness retinal penetration at all doses tested ranging from 0.5 to 30 mg. 12 Another reason for the observed differences may be the different techniques used to evaluate retinal penetration. The confocal microscope utilizes fluorescently labeled probes, is a very sensitive technique, and employs higher resolution to localize bevacizumab binding to individual cells than tissue autoradiography. The localization of bevacizumab binding to Muller and ganglion cells in the current study is consistent with prior localization of VEGF and VEGF receptors. 13 In addition, some of the cellular labeling within the inner retina may represent labeling of microglia or other cells capable of binding the Fc portion of bevacizumab. It is possible that a more sensitive assay would be able to detect bevacizumab within the retina at longer time points after injection as its concentration decreases, but for proof of concept that bevacizumab penetrates the retina in this model, the assay certainly seems sensitive enough. There is strong, specific labeling in the bevacizumab injected eyes for at least 7 days, whereas the control images at the same gain settings are completely black, without any labeling.
Finally, the clinically observed biologic effect of intravitreal bevacizumab may relate to the anatomy of the human foveola. Green has written that the ILM is greatly attenuated or absent over the foveola. 14, 15 Hogan et al state that its thickness drops to 10 to 20 nm in this region, whereas it is up to 40-fold thicker in the rest of the posterior pole. 16 In a primate study, the ILM thickness has been reported to be 30 nm at the foveal pit, but up to 2000 nm in the peripapillary area. 17 In addition, the retina is thinned at the foveola, and lacks an inner plexiform layer-a layer which has recently been shown to be a potential diffusion barrier to molecules of greater than 76 kD. 18 The attenuation of the ILM and the absence of an inner plexiform layer at the foveola may allow increased diffusion of bevacizumab in this region where it would be of greatest benefit in the treatment of ARMD.
The observation that there was less retinal labeling of bevacizumab at 7 days and no labeling by 28 days is expected given the half-life of an antibody in the vitreous cavity. Mordenti et al found no retinal labeling for the Fab fragment by 14 days as it had been cleared from the eye. 7 Direct comparison of the retinal penetration and affinity/binding of ranibizumab and bevacizumab in this model are subjects of future research, but this study shows that intravitreal bevacizumab can penetrate beyond the ILM into the retina.
The clinical observations did not show any inflammatory response in any injected eye. The lack of such response in the rabbit eye, which is much more prone to such inflammation than the human eye, may predict the lack of inflammation in human eyes as well. The electrophysiologic results demonstrate no functional damage to the retina of albino rabbits by intravitreal injection of bevacizumab. Even though only two case reports have been published thus far in the peerreviewed ophthalmologic literature, 8, 9 others are in press, 19 and personal communication reveals widely spreading off-label use of intravitreal bevacizumab worldwide. Thus far, no toxicity studies have been reported to support the safety for such intravitreal treatment. Our findings provide support from animal models for the use of this potentially breakthrough therapeutic modality.
The use of intravitreal bevacizumab is potentially preferable to the use of intravenous bevacizumab. First, intravitreal delivery of bevacizumab should lower the risk of systemic adverse effects associated with intravenous injection. Secondly, the dose needed for intravitreal injection is approximately 400-fold smaller compared with an intravenous dose. This will significantly lower the cost of treatment from approximately $2,200 USD per patient (using four vials); the cost of a 1 mg intravitreal dose is only $5.5 USD. 20 The use of intravitreal bevacizumab may also be more cost effective than other intravitreal antiangiogenic drugs such as pegaptanib and ranibizumab. It may potentially prove to be more efficacious than pegaptanib due to its ability to block all isoforms of VEGF as ranibizumab does. A potential advantage over ranibizumab is its predicted longer half life in the eye, thus requiring less frequent dosing. 6 It also may be an alternative in cases responding poorly to already approved treatment modalities for CNV.
Bevacizumab may prove desirable for primary treatment if future studies show better visual acuity results or the need for less frequent administration.
Based on electrophysiology, our study showed no evidence for retinal toxicity resulting from a single intravitreal injection of bevacizumab in a rabbit model. Extrapolation from animal to human studies should be done with caution. However, it should be noted that the dose injected in our study was twofold greater than that currently used in humans. Furthermore, the drug was injected into a smaller vitreous volume, less than 2 mL, in the rabbit as opposed to 4 to 5 mL in humans. Thus, our study supports the ocular safety of intravitreal bevacizumab injection.
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